Current issues in breast cancer

Current issues highlight some of the latest research into breast cancer, new therapies becoming available and new drug treatments coming to the market.

Raloxifene and breast cancer prevention Tamoxifen is well established therapy for breast cancer and has preventitive actions on the development of new primary breast cancers. However, there are small risks associated with its prolonged...
Letrozole approved for use after five years on Tamoxifen as adjuvant therapy for breast cancer The US Food and Drug administration has approved the drug letrozole ( an aromatase inhibitor) for the extended adjuvant treatment of post-menopausal women with breast cancer, who have received five...
Nanoparticle Taxol (paclitaxel) is more effective Homogenising paclitaxel (taxol) with human serum albumin under pressure produces nanoparticles that become a colloid when mixed with ordinary saline. Therapeutically these nanoparticles seem more...
Neoadjuvant Anastrazole permits higher breast conservation rates A recently reported trial (Immediate pre-ooperative arimidex compared to tamoxifen trial - IMPACT trial) reported that neoadjuvant anastrazole (an aromatase inhibitor) was more effective than...
Gene expression profiling predicts prognosis in breast cancer Doctors from USA and Holland used DNA microarrays to analyse gene expression in primary breast cancers from 117 young women. Seventy marker genes of interest were studied and based on the expressed...
Oral Ibandronate reduces the development of new bone metastases in breast cancer A recently reported study from Texas demonstrated that oral administration of ibandronate (a very potent third generation bisphosphonate) significantly reduced the incidence of new skeletal/bone...
Should Adjuvant Tamoxifen be delayed until after adjuvant chemotherapy in early breast cancer? For some time there has been a rumour that it is better to delay the start of tamoxifen until after the completion of any adjuvant post-operative chemotherapy. now, a good trial by the North American...
Taxane based chemo improves disease-free survival in high risk early breast cancer Early data from the Breast Cancer International Research Group suggests again that taxane based chemo has an 'up-front' role in the adjuvant therapy high risk early breast cancer. In a phase three...
Risk reducing Salpingo-oophorectomy in women with the brca 1/2 mutation in their genome Patients with the BRCA mutation in their genome are at a very high risk of developing breast or gynaecological cancer in their lifetime. Prophylactic mastectomies are considered in such patients, who...
Trial suggests that Tamoxifen may have a rival: Anastrazole For many years, tamoxifen has been the optimal form of endocrine (hormonal) therapy for breast cancer, and women who have oestrogen positive tumours (i.e. the cells express the oestrogen receptor on...

Page : [1] [2] [3]

« Previous | Next »